Thus, these findings provide evidences that LXN functions as a negative regulator of tumorigenesis and tumor immune escape, which expand the understanding of the antitumor effect of LXN previously unknown and provide a molecular mechanistic rationale for combining anti-PD-L2 immune-checkpoint therapy of tumor patients with low expression of LXN. Here, LXN is linked to neoplasm.